GRI · GRI Bio, Inc.
$1.47
+0.01 (+0.68%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$3.19M
Shares
2.19M
Volume · Oct 21
58.96K
Avg daily vol (3M)
325.56K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.47
Open$1.58
Day$1.46–1.58
52W close$1.38–63.28
Avg vol 30d76K
Short int69K · 3.2% float · 1.0d
Short vol14%
Last earningsFeb 11, 2026
DataFeb 2021–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$9.66M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 5,116.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$10.95M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2,191.8%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
3.2%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−40%
below
Price vs 50-day avg
−20%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−32%
trailing
6-month return
−33%
trailing
YTD return
−79%
this year
Relative strength
−40%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+83% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.18% of float · ▼ -40.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
11 holders — near 3-yr high, broad support
Squeeze score
36
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+92%
Y/Y
Free cash flow
$-10.2M
Balance sheet
$8.2M
net cash
Quant / Vol
risk profile
Volatility
127%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
10.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−40%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+83% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.18% of float · ▼ -40.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
11 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $63
vs 200-day avg -40%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRI
this stock
GRI Bio, Inc.
|
$3.19M | — | -100.0% | — | 3.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +15.7% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +733.5% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.4% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.22B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRI | +5.0% | -31.6% | -32.6% | -23.8% | -78.7% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | +4.6% | -32.3% | -40.1% | -25.2% | -92.1% |